Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBT (2016 - 2025)

Historic EBT for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $68.0 million.

  • Ironwood Pharmaceuticals' EBT rose 29161.72% to $68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.5 million, marking a year-over-year increase of 22612.72%. This contributed to the annual value of $167.1 million for FY2024, which is 11422.53% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' EBT is $68.0 million, which was up 29161.72% from $37.8 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' EBT's 5-year high stood at $125.9 million during Q4 2024, with a 5-year trough of -$1.1 billion in Q2 2023.
  • Its 5-year average for EBT is -$25.5 million, with a median of $46.3 million in 2021.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' EBT skyrocketed by 110651.72% in 2021, and later crashed by 210097.05% in 2023.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' EBT stood at $46.3 million in 2021, then skyrocketed by 56.23% to $72.3 million in 2022, then plummeted by 371.46% to -$196.2 million in 2023, then surged by 164.17% to $125.9 million in 2024, then tumbled by 45.97% to $68.0 million in 2025.
  • Its last three reported values are $68.0 million in Q3 2025, $37.8 million for Q2 2025, and -$36.3 million during Q1 2025.